Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections.

The Lupus Research Institute (LRI) has named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.

Finding the right skin care routine starts with understanding the unique needs of your skin type. For example, people with dry skin can benefit from applying moisturizer several times a day; whereas, those with oily skin might need to apply a lightweight moisturizer only once a day, if at all. Customization is key, and dermatologists [...]

TOPICA Pharmaceuticals, a privately-held biotechnology company, announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete’s foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with [...]

Scientists in China are reporting the “intriguing” discovery that a natural plant hormone, applied to crops, can help plants eliminate residues of certain pesticides. The study is scheduled for the Sept. 23 issue of ACS’ Journal of Agricultural and Food Chemistry, a bi-weekly publication.